BIOCRYST PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $1.32 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $1.32M, a 25.00% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $1.76M, a 52.64% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $3.73M, a 61.96% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $9.79M, a 63.38% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.32M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.76M 10-K · filed 2026-02-26 | $1.41M 10-K · filed 2025-02-25 |
| 2023-12-31 | $3.73M 10-K · filed 2026-02-26 | $3.30M 10-K · filed 2024-02-27 |
| 2022-12-31 | $9.79M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $5.99M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $4.08M 10-K · filed 2023-02-27 | |
| 2019-12-31 | $4.94M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $4.91M 10-K · filed 2021-03-01 | |
| 2017-12-31 | $1.98M 10-K · filed 2020-03-13 | |
| 2016-12-31 | $4.68M 10-K · filed 2019-03-14 | |
| 2015-12-31 | $10.45M 10-K · filed 2018-03-12 | |
| 2014-12-31 | $748.00K 10-K · filed 2017-02-27 | |
| 2013-12-31 | $1.21M 10-K · filed 2016-02-26 | |
| 2012-12-31 | -$829.00K 10-K · filed 2015-03-02 | $829.00K 10-K · filed 2013-03-11 |
| 2011-12-31 | -$2.11M 10-K · filed 2013-03-11 | |
| 2010-12-31 | -$5.36M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |